BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GenoMed, West Nile Virus, And Counting Crows


6/5/2006 12:22:24 PM

ST. LOUIS, June 5 /PRNewswire-FirstCall/ -- GenoMed , a Next Generation Disease Management company whose business is public health(TM), today underscored the discovery by Connecticut scientists that robins are the vector for West Nile virus in their state, not crows. Robins carry the virus without showing any symptoms, whereas crows get sick from the virus and die.

The same is true for human beings. Eighty percent of people with the virus have no symptoms at all, like robins. But 20% of people with viremia have symptoms: fever, headache, crushing fatigue. About a quarter of symptomatic patients progress to coma, and up to a third of people in coma die. The survivors have residual symptoms, including paralysis, for years later.

More like crows.

GenoMed has developed (and applied for patent protection on) a treatment for WNV that turns "crows" into robins. The Company uses safe, FDA-approved blood pressure pills to lower the immune response to the virus among the "crows" whose immune system overreacted to the virus.

GenoMed has used this treatment successfully for actual birds as well as people. This year the Company is extending its treatment to horses as well.

GenoMed published their initial results with 8 patients two years ago in a peer-reviewed medical journal. GenoMed's trial is now up to 22 patients; 19 have shown a rapid clinical response, for an 86% treatment success rate. GenoMed's success rate in birds is 50% so far (6 survivors, 6 deaths). It's lower because birds are found closer to death than humans.

It's therefore inaccurate for public health authorities to maintain that West Nile viral disease has no treatment. Public health authorities have limited themselves to counting dead crows and people since the epidemic began in 1999. Such pessimism hasn't been justified for the past 4 summers, once GenoMed introduced its novel treatment in May, 2003.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "GenoMed will offer its trial again for free this summer, since we'd like to collect more clinical outcomes data to convince the skeptics, especially the public health authorities. Anyone can download the trial protocol from our website, http://www.genomed.com, at any time of day or night. We simply request an email address to make clinical follow-up possible."

Added Dr. Moskowitz, "I'd appreciate it if anyone reading this could alert their friends to the existence of our trial. I'm sure they'd prefer singing like robins to croaking like crows."

About GenoMed

GenoMed uses genomics to better medicine(TM). A PDF file of the reference mentioned above is available upon request.

Safe Harbor Statement

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

GenoMed

CONTACT: David W. Moskowitz MD, CEO of GenoMed, +1-314-983-9938,dwmoskowitz@genomed.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES